DNMTs inhibitors play a role in reactivating excessively suppressed tumor suppressor genes, including p53 and p21, in cancer, thereby playing a crucial role in overcoming cancer treatment resistance (Fig. 8).515,781,782 Second-generation DNMT inhibitors with better pharmacokinetic properties, such as guadecitabine, have been developed. Here, TP53 is linked to cancer.